Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. (AZTR) announced that Co-founder and Chief Operating Officer Dr. Travis Whitfill will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York City.
He will provide an update on recent progress and key pipeline activities, including initial data from the ATR-COSF cosmetic protein program, which leverages Azitra’s microbial genetic engineering platform for applications such as fine lines and wrinkles. The presentation will also cover continued enrollment in the first cohort of the Phase 1/2 clinical trial of ATR-04, an investigational live biotherapeutic for EGFR inhibitor-associated rash, a condition impacting approximately 150,000 people in the U.S. During the conference, Dr. Whitfill plans one-on-one meetings with investors and potential partners to discuss business strategy, recent achievements, and anticipated milestones.
Azitra, Inc. (AZTR) announced that NYSE Regulation has confirmed the company has regained compliance with all NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide, resolving earlier deficiencies under Sections 1003(a)(ii) and 1003(a)(iii). The “below compliance” (.BC) indicator will be removed from Azitra’s trading symbol and the company will come off NYSE American’s list of noncompliant issuers. Azitra will remain subject to NYSE American’s continued listing monitoring procedures, and under Section 1009(h), any new noncompliance within 12 months could lead NYSE American to truncate normal compliance procedures or immediately initiate delisting proceedings.
Nantahala Capital Management, LLC and related reporting persons report beneficial ownership of 6,480,584 shares of Azitra, Inc. common stock as of June 30, 2026. This represents 9.99% of the outstanding common stock. The position includes 4,266,971 shares that may be acquired within sixty days through the exercise of convertible securities.
All reported shares are held with shared voting and dispositive power by Nantahala and its principals, Wilmot B. Harkey and Daniel Mack, and none are held with sole voting or dispositive power. Certain funds advised by Nantahala, including Blackwell Partners LLC – Series A and Nantahala Capital Partners Limited Partnership, have the right to receive dividends or sale proceeds from more than five percent of the outstanding common stock attributed to this beneficial ownership.
Nantahala Capital Partners Limited Partnership reported beneficial ownership of common stock of Azitra, Inc. As of June 30, 2026, Nantahala may be deemed to beneficially own 5,448,213 shares of Azitra, including 4,266,971 shares that may be acquired within sixty days upon exercise of warrants.
This position represents 8.40% of the class, based on 60,603,741 shares outstanding plus the warrant shares. All 5,448,213 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power.
Azitra, Inc. reported Q2 2026 results and outlined pipeline priorities in precision dermatology, cosmetics and biotechnology applications. Preclinical data from ATR-COSF showed repeat-dose delivery and anti-wrinkle activity in ex vivo human skin, supporting a planned human cosmetic application study starting in Q3 2026. The company continued enrolling the first cohort in its Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash, with topline data from the first cohort expected in Q4 2026, and advanced a recombinant protein portfolio including TEV Protease and T7 RNA Polymerase. Azitra plans to strategically pause further enrollment in the Phase 1b study of ATR-12 for Netherton syndrome to focus capital on programs with nearer-term opportunities. For Q2 2026, R&D expenses were $1.4 million, G&A expenses were $2.1 million, and net loss was $3.3 million versus $2.9 million a year earlier. As of June 30, 2026, cash and cash equivalents were $6.7 million and total stockholders’ equity was $7.3 million.
Azitra, Inc. is a pre-commercial synthetic biology company developing precision dermatology therapies using engineered microbes and proteins. For the six months ended June 30, 2026, it reported a net loss of $7.27 million, with operating expenses of $7.35 million and no product revenue. Operating cash use was $5.77 million, reflecting ongoing R&D and G&A spending.
Cash and cash equivalents rose to $6.73 million from $2.07 million at year-end 2025, driven mainly by a $10.4 million Series A preferred financing, warrant exercises and draws on an Equity Line of Credit, bringing total assets to $8.92 million and stockholders’ equity to $7.33 million. Shares outstanding increased to 60,603,742, and warrants outstanding reached 219,470,313, indicating significant potential dilution. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing cumulative losses of about $75.8 million and the need for additional financing despite current cash and access to approximately $13.8 million remaining under the Equity Line of Credit. Azitra also notes that its current equity level exceeds NYSE American minimums, though it remains under an exchange compliance plan.
Azitra, Inc. reported new ex vivo human skin data for its ATR-COSF program, a supernatant-based formulation containing recombinant human filaggrin (rHDfilaggrin). Repeat dosing of a 2% lyophilized supernatant hydrogel increased rHDfilaggrin penetration from the stratum corneum into the stratum granulosum compared with prior single-dose work, in a model using TH2-stimulated healthy skin explants.
In a second ex vivo model with defatted human skin, hydrogels containing the lyophilized supernatant increased elasticity in a dose-dependent manner. Formulations with 0.09% w/w and 7.5% w/w active ingredient produced about 1.6-fold and 4.4-fold elasticity enhancements, respectively, while around 0.28% w/w restored elasticity to values historically observed in healthy skin. A 0.3% w/w formulation produced approximately twice the elasticity of placebo. Standardized testing described the 2% formulation as non-irritating and non-corrosive to skin and eyes.
Azitra positions ATR-COSF as a high value cosmetic ingredient candidate and highlights a broader pipeline including ATR-04, an investigational live biotherapeutic for EGFR inhibitor–associated rash, which impacts approximately 150,000 people in the U.S.
Azitra, Inc. disclosure: Dauntless Investment Group, LLC filed a Schedule 13G reporting beneficial ownership of 5,804,636 shares of Azitra common stock, representing 9.58% of the class. The filer reports sole dispositive power over these shares and no voting power. The filing lists the filer as a "Single Family Office/Passive Investor" and is signed by the company's CFO on 06/25/2026.
Azitra, Inc.’s President and Chief Executive Officer, Francisco D. Salva, filed a Schedule 13D reporting a significant personal stake in the company. As of June 24, 2026, he beneficially owned 5,421,039 shares of common stock, representing 9.99% of the 52,907,666 shares outstanding.
His beneficial ownership includes 22,241 Incentive Stock Options and 1,334,748 shares underlying warrants that are exercisable within 60 days. It excludes 6,793,352 warrant shares that are not issuable within 60 days and are subject to a beneficial ownership limitation. Salva states he holds the securities for investment purposes but may buy or sell more shares depending on conditions.
Azitra, Inc. ownership disclosure: Stonepine entities and Jon M. Plexico report shared beneficial ownership of 1,744,339 shares of Common Stock, representing 9.9% of the class. The filing states the percentage "is giving effect to the 9.99% beneficial ownership limitation" and uses May 12, 2026 as the outstanding-share anchor of 16,192,438 shares.
The reporting persons note their holdings comprise 475,923 shares of Common Stock, Series A Preferred convertible into 27,107,210 shares, and Warrants to acquire 54,214,420 shares, each subject to a 9.99% beneficial ownership cap. Signatures show Jon M. Plexico as the reporting signatory.